• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)

    2/8/24 7:01:40 PM ET
    $ORTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ORTX alert in real time by email
    SC 13G/A 1 ortx13ga.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

     

    Orchard Therapeutics PLC

    (Name of Issuer)

     

     

    Ordinary Shares, nominal value £0.10 per share

    (Title of Class of Securities)

     

     

    68570P2001

    (CUSIP Number)

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

    1 This is the CUSIP number for the Issuer’s American Depositary Shares.

     1 
    CUSIP No. 68570P200

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 15,614,9902

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 15,614,9902

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 15,614,9902

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.9%

     

    12. Type of Reporting Person (See Instructions) IA, OO

    2 Represents 1,561,499 American Depositary Shares, each of which represents 10 Ordinary Shares of the Issuer.

     2 
    CUSIP No. 68570P200

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 15,614,9902

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 15,614,9902

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 15,614,9902

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.9%

     

    12. Type of Reporting Person (See Instructions) IA, PN

    2 Represents 1,561,499 American Depositary Shares, each of which represents 10 Ordinary Shares of the Issuer.

     3 
    CUSIP No. 68570P200

     

     

    1.Names of Reporting Persons.


    Beryl Capital Partners II LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)          

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 13,813,5503

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 13,813,5503

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 13,813,5503

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.1%

     

    12. Type of Reporting Person (See Instructions) PN

    3 Represents 1,381,355 American Depositary Shares, each of which represents 10 Ordinary Shares of the Issuer.

     4 
    CUSIP No. 68570P200

     

    1.Names of Reporting Persons.


    David A. Witkin

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 15,614,9902

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 15,614,9902

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 15,614,9902

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.9%

     

    12. Type of Reporting Person (See Instructions) IN, HC

    2 Represents 1,561,499 American Depositary Shares, each of which represents 10 Ordinary Shares of the Issuer.

     5 
    CUSIP No. 68570P200

    Item 1.

     

    (a)Name of Issuer

    Orchard Therapeutics PLC

     

    (b)Address of Issuer's Principal Executive Offices

    245 Hammersmith Road, London W6 8PW, United Kingdom

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Beryl Capital Management LLC (“Beryl”), Beryl Capital Management LP (“Beryl GP”), Beryl Capital Partners II LP (the “Partnership”) and David A. Witkin (collectively, the “Filers”). Each Filer disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at:

    225 Avenue I, Suite 205, Redondo Beach, CA 90277

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Ordinary Shares, nominal value £0.10 per share (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 68570P200

    This is the CUSIP number for the Issuer’s American Depositary Shares.

     

     6 
    CUSIP No. 68570P200

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E), as to Beryl and Beryl GP.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G), as to Mr. Witkin.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 227,610,439 Ordinary Shares outstanding as of November 9, 2023, as reported in the Form 10-Q filed by the Issuer on November 13, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Beryl is the investment adviser to the Funds and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Material to Be Filed as Exhibits

    Exhibit A Joint Filing Agreement.

    Item 11.Certification of Beryl, Beryl GP and Mr. Witkin.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     7 
    CUSIP No. 68570P200

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 8, 2024

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By: /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson
      Chief Operating Officer and CFO       Andrew Nelson
            Chief Operating Officer and CFO
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By:/s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    
     8 
    CUSIP No. 68570P200

     

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G and Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Beryl Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

     

    Dated: February 8, 2024

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By: /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson
      Chief Operating Officer and CFO       Andrew Nelson
            Chief Operating Officer and CFO
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By:/s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    

     

     

    Get the next $ORTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORTX

    DatePrice TargetRatingAnalyst
    12/29/2021$12.00 → $9.00Overweight
    Cantor Fitzgerald
    11/16/2021Neutral → Underweight
    JP Morgan
    11/5/2021$15.00 → $13.00Outperform
    Oppenheimer
    8/18/2021Overweight → Neutral
    JP Morgan
    More analyst ratings

    $ORTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024

      TOKYO, LONDON and BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced four oral and four poster presentations from across its hematopoietic stem cell (HSC) gene therapy platform will be featured at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 7-11, 2024, in Baltimore. Featured data include several accepted abstracts and an Oral Presidential Symposium supporting the safety and efficacy of atidarsagene autotemcel (formerly OTL-200 which was recently approved as Lenmeldy™ in the

      5/7/24 7:00:17 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

      TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, has been named to the inaugural 2024 TIME100 Health, an annual list recognizing the impact, innovation, and achievement of the world's most influential individuals in health this year. The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/. "I am incredibly humbled, privileged, and immensely proud to b

      5/3/24 7:00:38 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

      Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout the treatment process Lenmeldy wholesale acquisition cost of $4.25 million for one-time treatment reflects its clinical, economic and societal value Innovative outcomes- and value-based agreements are being offered to both private and government insurers to ensure broad, expedient and sustainable reimbursed access TOKYO, LONDON and BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the de

      3/20/24 7:00:07 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Orchard Therapeutics plc

      15-12G - Orchard Therapeutics plc (0001748907) (Filer)

      2/5/24 2:39:49 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Orchard Therapeutics plc

      EFFECT - Orchard Therapeutics plc (0001748907) (Filer)

      1/31/24 12:15:05 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Orchard Therapeutics plc

      EFFECT - Orchard Therapeutics plc (0001748907) (Filer)

      1/31/24 12:15:12 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Orchard Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of Orchard Therapeutics with a rating of Overweight and set a new price target of $9.00 from $12.00 previously

      12/29/21 7:21:48 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Orchard Therapeutics downgraded by JP Morgan

      JP Morgan downgraded Orchard Therapeutics from Neutral to Underweight

      11/16/21 5:23:39 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Orchard Therapeutics with a new price target

      Oppenheimer reiterated coverage of Orchard Therapeutics with a rating of Outperform and set a new price target of $13.00 from $15.00 previously

      11/5/21 9:48:29 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    Financials

    Live finance-specific insights

    See more
    • Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases

      TOKYO and LONDON and BOSTON, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) discovering and developing novel medicines utilizing the latest biotechnology, and Orchard Therapeutics plc ((Orchard Therapeutics, NASDAQ:ORTX), a global gene therapy leader, today announced Kyowa Kirin has successfully completed the acquisition of Orchard Therapeutics. The acquisition of all outstanding shares of Orchard Therapeutics by way of a Scheme of Arrangement procedure under the UK Companies Act 2006 was completed on January 24, 2024, and Orchard Therapeutics has become a wholly-owned subsidiary of Kyowa Kirin.

      1/24/24 5:00:00 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kyowa Kirin to Acquire Orchard Therapeutics

      -Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin's portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel)--Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a total maximum equity value of approximately $477.6 million--Kyowa Kirin to host investor conference call on Oct 5 at 18:30 p.m. JST- TOKYO and LONDON and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Ky

      10/5/23 3:35:06 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA

      Reported $6.6M in Q2'23 Libmeldy net sales, representing the highest quarter to date $34.0M of additional capital from second closing of strategic financing extends runway to mid-2025 Four MLD patients identified from ~150,000 newborns screened in prospective studies suggests significantly higher incidence than previously estimated in the medical literature Six presentations at ASGCT demonstrate the ability of HSC gene therapy to address neurometabolic and CNS disorders, as well as larger indications Company to host conference call and live webcast today at 8:00 a.m. EDT BOSTON and LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene th

      8/3/23 7:00:09 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Orchard Therapeutics plc

      SC 13G - Orchard Therapeutics plc (0001748907) (Subject)

      2/14/24 9:05:44 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)

      SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)

      2/14/24 6:35:58 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Orchard Therapeutics plc (Amendment)

      SC 13G/A - Orchard Therapeutics plc (0001748907) (Subject)

      2/12/24 12:03:27 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Secor Alicia

      4 - Orchard Therapeutics plc (0001748907) (Issuer)

      1/24/24 5:34:09 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Geraghty James A returned 44,391 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Orchard Therapeutics plc (0001748907) (Issuer)

      1/24/24 5:29:38 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Thomas Frank E returned 92,081 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Orchard Therapeutics plc (0001748907) (Issuer)

      1/24/24 5:27:31 PM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ORTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments

      Reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date Planned acquisition by Kyowa Kirin valued at up to $477.6 million with an anticipated closing in the first quarter of 2024 Biologics License Application for OTL-200 in MLD accepted by U.S. FDA under Priority Review; PDUFA date set for March 18, 2024 Ten prospective newborn screening studies are active globally with approximately 200,000 babies screened Eight presentations at ESGCT highlighted the differentiated profile and potential broad applicability of the company's HSC gene therapy platform BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene the

      11/13/23 7:00:00 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension

      PRESS RELEASE OMass Therapeutics Announces Appointment of New Board Chairand Series B Extension Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair of multiple listed biotechsBritish Patient Capital invests £10 million in a Series B extension bringing total raised in this round to £85.5 million Oxford, United Kingdom – 15 May 2023 – OMass Therapeutics (‘OMass', or ‘the Company'), a biotechnology company that identifies medicines against highly validated target ecosystems, today announces the appointment of Jim Geraghty as chairman of its board of directors and an additional investment of £10 million from new inve

      5/15/23 2:00:00 AM ET
      $FULC
      $ORTX
      $PIRS
      $VYGR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments

      Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie Meltzer, Ph.D., promoted to chief medical officer Appointments reinforce company's strategic focus on innovation in the areas of discovery, clinical development and manufacturing BOSTON and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ:ORTX), a global gene therapy leader, today announced the appointment of two gene therapy and industry experts, Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., to serve as chief scientific officer and chief technical officer, respectively

      9/9/21 7:00:00 AM ET
      $ORTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care